Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
| | |||
Accelrys Inc. (subsidiary of Pharmacopeia Inc.; ACCL) |
Henkel KGaA (Germany) |
Three-year license deal under which Henkel will use Accelrys' Materials Studio software |
The deal builds on a relationship in which Henkel was a member of Accelrys' Formulations Consortium to develop software solutions; terms were not disclosed (3/9) |
Advancis Pharmaceutical Corp. (AVNC) |
Par Pharmaceuticals Inc. |
Companies signed a letter of intent to develop Advancis' Amoxicillin Pulsys |
Par would pay $5M up front and fund further development in exchange for co-marketing rights; they would share marketing expenses and revenues, and Advancis would manufacture the product (3/2) |
Affymetrix Inc. (AFFX) |
Aventis SA (France) |
Agreement that provides Aventis early access to the GeneChip High-Throughput Array |
Terms of the deal were not disclosed (3/3) |
Alliance Pharmaceutical Corp. (OTC BB:ALLP) |
Nycomed Danmark ApS (Denmark) |
Nycomed will develop and commercialize the snythetic oxygen carrier Oxygent in Europe |
Nycomed also gained an option to rights in China; Alliance would get a royalty on sales; further terms were not disclosed (4/5) |
Amphora Discovery Corp.* |
Aventis SA (France) |
Two-year deal for lead generation across Aventis' global research sites; Amphora will identify small-molecule kinase inhibitors for multiple targets |
Amphora gets research funding and potential milestones and royalties; Aventis has an option to extend the deal (3/30) |
Anadys Pharmaceuticals Inc. (ANDS) |
LG Life Sciences Ltd. (South Korea) B infection |
Anadys acquired exclusive rights to LB80380 (ANA380) for treating chronic hepatitis |
The rights include most of the world, including Japan but excluding certain other countries in Asia; they will jointly fund global development; specific terms were not disclosed (4/19) |
AnorMed Inc. (Canada; TSE:AOM) |
Shire Pharmaceuticals Group plc (UK) |
AnorMed is selling Shire the global patents for Fosrenol |
Shire would pay $18M when the product is approved in the U.S. and $7M when approved in Europe; Shire's royalty obligations ended except in Japan, where it has an option to purchase patents for $6M (3/23) |
Antigenics Inc. (AGEN) |
Virbac SA (France) |
Antigenics sold its manufacturing rights for feline leukemia virus vaccine |
Virbac, which has had exclusive marketing rights to the product since 1983, paid $14.25M in cash for all remaining rights (3/18) |
Antisoma plc (UK; LSE:ASM) |
Inverness Medical Innovations Inc. |
Antisoma acquired certain royalty rights to products based on mouse and humanized variants of the antibody HMFG1, on which the producs R1549 and R1550 are based |
The drugs are being developed by Antisoma and F. Hoffmann-La Roche Ltd.; Antisoma paid $300,000 up front and will pay up to $1.5M in milestones to Inverness, which relinquished its royalty rights; Antisoma's royalty potential increased to 2.66% and 1.5%, respectively (4/21) |
Arachnova Therapeutics Ltd.* (UK) |
Mitsubishi Pharma Corp. (Japan) |
License deal giving Arachnova rights to use MCI-225 in pain, stress urinary incontinence and functional bowel disorder |
Mitsubishi had taken the compound to Phase II in depression; Arachnova found the new uses, and gets access to Mitsubishi data under undisclosed terms (3/16) |
Arachnova Therapeutics Ltd.* (UK) |
Sosei Co. Ltd. (Japan) |
Licensing deal involving the new therapeutic use of AA10020/SOU001 for stress urinary incontinence |
Sosei is paying up-front fees and potential milestones and royalties in exchange for exclusive worldwide rights; Arachnova's computational prediction technology helped establish the drug's new use (2/25) |
ArQule Inc. (ARQL) |
Roche Holdings Ltd. (Switzerland) |
Partnership to discover and develop drugs targeting the E2F pathway in order to selectively kill cancer cells |
Roche is paying $15M up front and providing development support; ArQule will take drugs to Phase II, when Roche could option them for a fee; ArQule could receive up to $276 million for a successful product, as well as royalties, and has a co-promotion option for the U.S. (4/2) |
Array BioPharma Inc. (ARRY) |
Takeda Chemical Industries Ltd. (Japan) |
Collaboration to create a series of small-molecule drug leads against a Takeda target |
Array will receive fees for research work and is entitled to milestone and royalty payments; the deal is in addition to their collaboration that began in 2001 (4/5) |
Astex Technology Ltd.* (UK) |
Boehringer Ingelheim GmbH (Germany) |
Three-year, multitarget alliance covering various indications; the deal combines Astex's fragment- based discovery with BI targets |
BI will make an up-front payment to Astex and will fund research, as well as make milestone and royalty payments as earned, in exchange for worldwide rights (3/9) |
Atrix Laboratories Inc. (ATRX) |
Aventis SA (France) |
Limited feasibility deal to study two Aventis compounds formulated in Atrix's Atrigel delivery technology |
Details on the deal and the therapeutic areas of focus were not disclosed (3/16) |
Attenuon LLC* |
Kirin Brewery Co. Ltd. (Japan) |
Collaboration to develop fully human monoclonal antibodies for therapeutic and diagnostic applications in oncology |
Attenuon will receive research funding, while rights to resulting products will be shared; each company maintains owner- ship of its technology (2/24) |
Auxilium Pharmaceuticals Inc.* |
Ipsen SA (France) |
Ipsen gained marketing rights to Testim testosterone gel everywhere but North America and Japan |
Auxilium is entitled to milestone and royalty payments; specific terms were not disclosed (4/6) |
Biotie Therapies Corp.* (Finland) |
Aventis SA (France) |
Research and option agreement for joint development of a product to prevent and treat blood-coagulation disorders |
Biotie is getting $8.8M in license and milestone fees over 12 months in exchange for Aventis getting exclusive rights to negotiate a license agreement for the bioheparin product (3/9) |
BioVision AG* (Germany) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Roche got a nonexclusive license to BioVision's Differential Peptide Display technology |
The technology allows for visualizing the peptides and small proteins within a sample and to analyze changes; terms of the deal were not disclosed (3/3) |
Cengent Therapeutics Inc.* |
Novartis Pharma AG (Switzerland) |
Cengent will screen for drug candidates against multiple Novartis targets |
Cengent will get undisclosed up-front and milestone payments; Cengent will use its Genes To Leads technology in the deal (4/12) |
ChemoCentryx Inc.* |
Forest Laboratories Inc. |
Collaboration to develop small- molecule therapeutics for auto- immune and inflammatory diseases; the focus is on the CCR1 chemokine receptor |
Forest gets a license to ChemoCentryx drugs in exchange for cash and equity payments up front; Forest will fund the work for three years, and make research, milestone and royalty payments; ChemoCentryx has co- promotion options (3/15) |
Commonwealth Biotechnologies Inc. (CBTE) |
DynPort Vaccine Co. LLC |
Two-year deal in which they will work together to compete for biodefense vaccine development funding |
The companies already are working on three projects together (3/30) |
Corixa Corp. (CRXA) |
Aventis SA (France) |
Aventis Pasteur gets coexclusive and nonexclusive worldwide rights to Corixa's RC-529 adjuvant in multiple diseases |
Corixa gets up-front license fees and success-based milestones and royalties; Aventis committed to annual orders for the product, and later could add additional nonexclusive vaccine fields (3/30) |
Corixa Corp. (CRXA) |
Abbott Laboratories |
Abbott got nonexclusive rights to Corixa's TcF antigen for use in an assay to detect antibodies to Trypanosoma cruzi |
It is the sixth license deal between the companies; all involve up-front fees and potential milestones and/or royalties (3/2) |
Cougar Biotechnology Inc.* |
BTG plc (UK) |
Cougar gained worldwide rights to abiraterone acetate, a drug being developed for advanced prostate cancer |
BTG gets an up-front payment and potential milestones and royalties; terms were not disclosed (4/20) |
Cyprotex plc (UK; LSE:CRX) |
Solvay SA (Belgium) |
Cyprotex will screen compounds for Solvay and provide information on ADME properties |
Cyprotex will use its Cloe Screen technology in the deal, terms of which were not disclosed (2/19) |
DeCode Genetics Inc. (Iceland; DCGN) |
Merck & Co. Inc. |
Seven-year alliance under which DeCode will use its genetics and genomics technologies to complement Merck clinical trials |
Merck purchased $10M of DeCode stock at $14.50 per share and has a warrant to buy up to $50M more stock at $29 per share over five years; DeCode gets a technology- access fee and potential milestones and royalties; they also may pursue development of pharmacogenomic tests (2/26) |
Eidogen Inc.* |
Boehringer International GmbH (Germany) |
BI got a pilot license to Eidogen's Target Informatics Platform software |
The product is a structural informatics enterprise software solution; terms were not disclosed (3/30) |
Evotec OAI AG (Germany; FSE:EVT) |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
Evotec will identify, synthesize and optimize compounds that show activity against one of Fujisawa's drug targets |
Evotec will receive fees for services and potential milestone payments; specific terms and targets were not disclosed (4/13) |
Evotec Neurosciences GmbH (subsidiary of Evotec OAI AG; Germany; FSE:EVT) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Evotec acquired an exclusive worldwide license to patents covering NMDA receptor NR2B subtype selective antagonists for treating CNS disorders |
Roche retained the right to reacquire the compounds, which are in preclinical development; terms of the deal were not disclosed (3/25) |
Gastrotech Pharma A/S* (Denmark) |
Eli Lilly and Co. |
Companies entered deal to continue developing peptides for irritable bowel syndrome and functional dyspepsia |
Lilly will manufacture the glucagon-like peptide-1 analogue that is in Phase II trials in IBS, and has an option to further develop and commercialize the product in exchange for milestone and royalty payments (3/31) |
Genzyme Corp. (GENZ) |
Procter & Gamble Pharmaceuticals Inc. |
P&G got an exclusive world- wide license to RDP58 for gastrointestinal and other disorders |
Genzyme gets $10M up front and potential milestone payments; Genzyme got the drug through its acquisition of SangStat Medical Corp. in September 2003 (4/1) |
Gloucester Pharmaceuticals Inc.* |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
Gloucester acquired exclusive worldwide rights to the deacetylase inhibitor FK228 as a cancer agent |
Fujisawa receives an up-front license fee and potential milestone payments and royalties; the product is in Phase II trials in two cancer indications (4/15) |
GTx Inc. (GTXI) |
Ortho Biotech Products LP (Johnson & Johnson) |
Collaboration and license deal covering andarine, GTx's lead selective androgen receptor modulator, and certain backup SARM compounds |
GTx will receive an up-front licensing fee, additional licensing fees and milestone payments up to $82 million for andarine and up to $45 million for each additional licensed compound; J&J gets a worldwide exclusive license and will take over further development; GTx has U.S. co-promotion options in men's health areas, and would get double-digit royalties (3/17) |
Indevus Pharmaceuticals Inc. (IDEV) |
Pliva d.d. (Croatia) |
Deal giving Pliva subsidiary Odyssey Pharmaceuticals Inc. U.S. rights to Sanctura, a product for overactive bladder that is under FDA review |
Indevus gets $30M up front and would get $120M upon FDA approval; it also could earn another $65M in longer-term milestones; Indevus will create a sales force to co-promote the product (4/7) |
Ingenium Pharmaceuticals AG* (Germany) |
Merck & Co. Inc. |
Ingenium will provide Merck genetic rat models with alterations in a gene specified by Merck |
Further details of the deal were not disclosed (4/1) |
Inpharmatica Ltd.* (UK) |
Taisho Pharmaceuticals Co. Ltd. (Japan) |
Taisho subscribed to the online Biopendium product containing sequence data |
Terms of the deal were not disclosed (3/29) |
Inpharmatica Ltd.* (UK) |
GlaxoSmithKline plc (UK) |
Inpharmatica will apply its in silico ADME technology to undisclosed GSK discovery programs |
Terms of the deal were not disclosed (3/22) |
InterMune Inc. (ITMN) |
Baxter Healthcare Corp. |
Deal for InterMune to co- promote Aralast to pulmonologists in the United States |
InterMune will detail the alpha-1 proteinase inhibitor for the treatment of hereditary emphysema; terms were not disclosed (3/29) |
Kereos Inc.* |
Bristol-Myers Squibb Co. |
Agreement to develop and sell molecular imaging agents based on Kereos technology |
BMS got exclusive rights to cardiovascular agents and Kereos got rights to use BMS targeting molecules for cancer imaging agents and targeted therapeutics; terms were not disclosed (3/2) |
LifeCycle Pharma A/S* (Denmark) |
Recordati SpA (Italy) |
Deal to develop a modified- release formulation of Recordati's hypertension drug Zanidip |
LifeCycle will apply its MeltDose technology to the effort, and also will develop the manufacturing process; it is entitled to undisclosed milestones and royalties (4/1) |
MediciNova Inc.* |
Kissei Pharmaceutical Co. Ltd. (Japan) |
MediciNova obtained exclusive rights outside of Japan to KUR- 246 (MN-221), a compound in Phase II for premature labor |
MediciNova is making undisclosed up-front, milestone and royalty payments to Kissei (2/25) |
NeoGenesis Pharmaceuticals Inc.* |
AstraZeneca plc (UK) |
Collaboration under which NeoGenesis will use its discovery technologies to find candidates for selected diseases |
NeoGenesis will get undisclosed research funding, R&D milestones and royalties on any sales; specific terms were not disclosed (3/25) |
Neose Technologies Inc. (NTEC) |
BioGeneriX AG (Germany; unit of Ratiopharm Group) |
Deal to use Neose's GlycoPEG-ylation technology to develop a next-generation version of granulocyte-colony stimulating factor |
BioGeneriX will fund any clinical development in exchange for rights outside North America and Japan; Neose gets an up-front fee and each company would pay the other royalties from sales in its territory (4/20) |
Neurocrine Biosciences Inc. (NBIX) |
Wyeth |
Neurocrine purchased all of Wyeth's financial interest in indiplon, a late-stage insomnia candidate |
Wyeth gets $50m in cash and $45M in Neurocrine stock priced at a 15-day average; Wyeth's rights, gained from a deal with DOV Pharmaceutical Inc., move to Neurocrine, which will see its royalty obligations reduced from 6% to 3.5% (2/26) |
NexMed Inc. (NEXM) |
Unnamed Japanese company |
NexMed will provide contract development services for a topical product to treat a form of herpes |
NexMed received up-front funding and is eligible to receive milestone payments (3/31) |
NPS Pharmaceuticals Inc. (NPSP) |
Nycomed Group (Denmark) |
Nycomed gained rights to the osteoporosis drug Preos in Europe |
Nycomed is making an equity investment of $25M in NPS, paying up to $25M in regulatory and sales milestones, and paying NPS royalties on sales; it also will conduct Phase IIIb and IV studies in Europe (4/21) |
Odyssey Thera Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Deal to profile certain Roche compounds across Odyssey's cell-based assays |
The focus is to further characterize mechanism of action and pathway activity; terms were not disclosed (4/8) |
OriGene Technologies Inc.* |
Genomics Institute of the Novartis Research Foundation |
Novartis purchased the True- Clone collection of full-length human cDNA clones |
Novartis will use the clones in its high- throughput discovery efforts; terms were not disclosed (3/9) |
Ovation Pharmaceuticals Inc.* |
Aventis SA (France) |
Ovation acquired North American rights to the CNS drugs Sabril (vigabatrin) and Frisium (clobazam) |
Ovation paid cash in the deal, terms of which were not disclosed; both products are approved in Canada and Mexico, but not in the U.S. (4/5) |
Pharming Group NV (the Netherlands; Euronext:PHARM) and Greece |
Laboratorios del Dr. Esteve SA (Spain) |
Companies signed letter of intent giving Dr. Esteve rights to recombinant human C1 inhibitor in Spain, Portugal |
Pharming can get milestones, royalties and contributions to R&D costs; the deal is expected to be finalized by June 30 (4/19) |
PPL Therapeutics plc (LSE:PPH) |
Exeter Life Sciences Inc. |
PPL sold Exeter its rights to Revivicor Holdings Inc.'s gene- targeting technology in the field of protein production |
PPL is receiving $150,000 in the deal under which it is disposing of the asset (2/25) |
Protein Mechanics Inc.* |
Aventis SA (France) |
Agreement to advance the discovery and validation of highly selective, orally available matrix metalloprotease inhibitors |
Protein Mechanics will use its predictive simulation technology in the deal, terms of which were not disclosed (3/23) |
Proteome Sciences plc (UK; LSE:PRM) |
Bayer Pharmaceuticals |
Proteome licensed certain biomarkers in Alzheimer's disease |
Bayer discovered the markers with the University Cantonal Hospital in Switzerland; terms were not disclosed (3/23) |
QRx Pharma Pty. Ltd.* (Australia) |
Shire Pharmaceuticals Group plc (UK) |
Shire will develop extended- release formulations of QRx's opioid product, Q8003 |
QRx is nearing Phase III trials of an immediate-release version of the drug; terms were not disclosed (3/24) |
SemBioSys Genetics Inc.* |
Syngenta SA (Switzerland) |
Syngenta gets access to SemBioSys' oil body-based systems for developing biologic products |
The deal involves an up-front payment to SemBioSys and potential option-exercise fees, milestones and royalties (2/24) |
SkyePharma plc (UK;SKYE) |
Medeus Pharma Ltd. (UK) |
Deal under which Medeus will market DepoMorphine in Europe; a marketing application has been filed for the drug, a morphine formulation |
SkyePharma stands to get 35% to 50% of sales, and milestone payments up to $120M; Medeus will pay for manufacturing and sales and be responsible for attaining approvals throughout the EU (4/5) |
Solvo Biotechnology Inc.* (Hungary) |
MDS Pharma Services (unit of MDS Inc.) |
They will provide multidrug- resistance transporter assays for screening and lead optimization and ADME studies |
Solvo's ATP-binding cassette transporter protein assays complement MDS's in vitro metabolism services; terms were not disclosed (4/14) |
SuperGenInc. (SUPG) |
Pfizer Inc. |
SuperGen acquired European rights to the cancer drug Nipent, which it already sells in the U.S. |
The drug is approved for hairy-cell leukemia and is being studied in a number of hematologic malignancies; terms were not disclosed (2/24) |
Theravance Inc.* |
GlaxoSmithKline plc (UK) |
Broadened deal covering a variety of therapeutic areas; GSK has an option for all current and future programs through August 2007 |
Theravance gets $129M up front, much of which increases GSK's stake to 19% from 6%; Theravance is eligible for milestones of $162M to $240M per program; the deal also includes a put/call arrangement under which GSK's stake could increase up to 60% in 2007 (3/31) |
ThromboGenics Ltd.* (Ireland) |
Geymonat SpA (Italy) |
Agreement for co-development of placental growth factor, an angiogenesis agent to which each firm has certain rights |
The goal of the joint effort is to bring the product into the clinic, and then attract a partner; specific terms were not disclosed (3/3) |
Unigene Laboratories Inc. (OTC BB:UGNE) |
Novartis Pharma AG (Switzerland) |
Novartis gained rights to produce recombinant calcitonin under Unigene's manufacturing process |
Unigene will sell calcitonin to Novartis to support Novartis' development programs, while remaining free to develop its own products; Unigene gets $5.6M up front and up to $18.7M in the deal, as well as potential royalties (4/8) |
Vela Pharmaceuticals Inc.* |
Otsuka Pharmaceutical Co. Ltd. (Japan) |
Vela gained rights in the U.S. and Europe for a Phase II compound to treat depression |
VelaPharm designated the drug VPI- 013 and plans a Phase II trial in June; terms of the deal were not disclosed (4/1) |
Vernalis plc (UK; VNLS) |
Elan Corp. plc (Ireland) |
Vernalis is reacquiring all North American rights to frovatriptan |
Vernalis is paying $50M to Elan through 2005; it plans to find a new partner for the product, which is approved for treating migraine (3/30) |
Vion Pharmaceuticals Inc. (VION) |
Johnson & Johnson Consumer Companies Inc. |
J&J got a worldwide, non-exclusive license to Vion's Melasyn, a synthetic form of melanin |
No up-front or milestone payments were included in the deal, but Vion would get royalties on any resulting sales where it holds patent rights (3/15) |
Xechem International Inc. (OTC BB:XKEM) |
Alembic Ltd. (India) |
Agreement to bring Nicosan/ Hemoxin to market for treating sickle cell disease |
Alembic is providing Xechem $3.6M; Alembic is entitled to royalties, gained a 15% stake in Xechem's Nigerian subsidiary, and has first refusal rights to distribute the product in India and Africa (4/5) |
ZymoGenetics Inc. (ZGEN) |
Novo Nordisk A/S (Denmark) |
Novo licensed exclusive North American rights to ZymoGenetics' patents covering interleukin-20 |
Novo is paying $4M up front and would make milestone and royalty payments as warranted; Novo licensed IL-20 rights for the rest of the world in 2001 (3/16) |
|
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
